Role of ADME Characteristics in Drug Discovery and Their In Silico Evaluation: In Silico Screening of Chemicals for their Metabolic Stability

V.K. Gombar; I.S. Silver; Z. Zhao
July 2003
Current Topics in Medicinal Chemistry;Jul2003, Vol. 3 Issue 11, p1205
Academic Journal
Drug discovery is a long, arduous process broadly grouped into disease target identification, target validation, high-throughput identification of "hits" and "leads", lead optimization, and pre-clinical and clinical evaluation. Each area is a vast discipline in itself. However, all but the first two stages involve, to varying degrees, the characterization of absorption, distribution, metabolism, excretion, (ADME), and toxicity (T) of the molecules being pursued as potential drug candidates. Clinical failures of about 50% of the Investigational New Drug (IND) filings are attributed to their inadequate ADMET attributes. It is, therefore, no surprise that, in the current climate of social and regulatory pressure on healthcare costs, the pharmaceutical industry is searching for any means to minimize this attrition. Building mathematical models, called in silico screens, to reliably predict ADMET attributes solely from molecular structure is at the heart of this effort in reducing costs as well as development cycle times. This article reviews the emerging field of in silico evaluation of ADME characteristics. For different approaches that have been employed in this area, a critique of the scope and limitations of their descriptors, statistical methods, and reliability are presented. For instance, are geometry-based descriptors absolutely essential or is lower-level structure quantification equally good? What advantages, if any, do we have for methods like artificial neural networks over the least squares optimization methods with rigorous statistical diagnostics? Is any in silico screen worth application, let alone interpretation, if it is not adequately validated? Once deemed acceptable, what good is an in silico screen if it cannot be made available at the workbench of drug discovery teams distributed across the globe throughout multi-national pharmaceutical companies? These are not mere discussion points, rather this article embarks on the stepwise mechanics of developing a successful in silico screen. The process is exemplified by our efforts in developing one such screen for predicting metabolic stability of chemicals in a human S9 liver homogenate assay. A real-life use of this in silico screen in a variety of discovery projects at GlaxoSmithKline is presented, highlighting successes and limitations of such applications. Finally, we project some capabilities of in silico ADME tools for greater impact and contribution to successful, efficient drug discovery.


Related Articles

  • Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence? Williams, J. Andrew; Hurst, Susan I.; Bauman, Jonathan; Jones, Barry C.; Hyland, Ruth; Gibbs, John P.; Obach, R. Scott; Ball, Simon E. // Current Drug Metabolism;Dec2003, Vol. 4 Issue 6, p527 

    For the pharmaceutical industry, one of the challenges in evaluating the risk of future compound attrition at the discovery stage is the successful prediction of the major routes of clearance in humans. For compounds cleared by metabolism, such information will help to avoid the development of...

  • Opportunities for Personalized Medicine in Cancer Trials. Weisberg, Jeffrey; Morrison, Mark // Applied Clinical Trials;May2007 Supplement, Vol. 16, p12 

    The article focuses on the benefits of personalized medicine for improving oncology studies. According to the author, personalized medicine considerations are very important to oncology trials due to the narrow therapeutic index of the cancer drugs. In general, personalized medicine takes into...

  • Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. Pavithra, B. H.; Prakash, N.; Jayakumar, K. // Journal of Veterinary Science;2009, Vol. 10 Issue 4, p293 

    investigation was carried out in adult New Zealand white rabbits to study the influence of curcumin pre-treatment on pharmacokinetic disposition of norfioxacin following single oral administration. Sixteen rabbits were divided into two groups of eight each consisting of either sex. Animals in...

  • A Perspective on Reconciling Mass Balance in Forced Degradation Studies. Lukulay, Patrick; Hokanson, Gerard // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p106 

    Focuses on two scenarios that demonstrate the need to use the percent of parent drug loss rather than the percent of degradation products formed when reconciling mass balance calculations. Quality control check on analytical methods to show that all degradation products are adequately detected...

  • Drug Metabolic Enzymes in Developmental Toxicology1. MILLER, MARK STEVEN; JUCHAU, MONT R.; GUENGERICH, F. PETER; NEBERT, DANIEL W.; RAUCY, JUDY L. // Fundamental & Applied Toxicology;1996, Vol. 34 Issue 2, p165 

    Although much is known about the metabolism of environmental toxicants in adult organisms, little information exists on the role of cytochrome P450 (CYP) enzymes during development. The developing organism is remarkably dynamic, presenting a constantly changing metabolic profile as various...

  • Clinical pharmacokinetics of oxcarbazepine. May, Theodor W.; Korn-Merker, Elisabeth; Rambeck, Bernhard // Clinical Pharmacokinetics;Sep2003, Vol. 42 Issue 12, p1023 

    Oxcarbazepine is an antiepileptic drug with a chemical structure similar to carbamazepine, but with different metabolism. Oxcarbazepine is rapidly reduced to 10,11-dihydro-10-hydroxy-carbazepine (monohydroxy derivative, MHD), the clinically relevant metabolite of oxcarbazepine. MHD has (S)-(+)-...

  • Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin. Fareed, Jawed; Hoppensteadt, Debra; Walenga, Jeanine; Iqbal, Omer; Qing Ma; Jeske, Walter; Sheikh, Taqdees // Clinical Pharmacokinetics;Sep2003, Vol. 42 Issue 12, p1043 

    Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties. Some of the pharmacodynamic features of enoxaparin that distinguish it from UFH are a higher ratio of anti-Xa to anti-IIa...

  • A Model of the Kinetics of Lanthanum in Human Bone, Using Data Collected during the Clinical Development of the Phosphate Binder Lanthanum Carbonate. Bronner, Felix; Slepchenko, Boris M.; Pennick, Michael; Damment, Stephen J. P. // Clinical Pharmacokinetics;2008, Vol. 47 Issue 8, p543 

    Objective: Lanthanum carbonate (Fosrenol®) is a non-calcium phosphate binder that controls hyperphosphataemia without increasing calcium intake above guideline targets. The biological fate and bone load of lanthanum were modelled with the aid of a four-compartment kinetic model, analogous to...

  • Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate: Randomized, Open-Label, Crossover, Single-Centre Study in Healthy Volunteers. Fontes-Ribeiro, Carlos; Macedo, Tice; Nunes, Teresa; Neta, Carla; Vasconcelos, Teófilo; Cerdeira, Rui; Lima, Ricardo; Rocha, José-Francisco; Falcão, Amílcar; Almeida, Luís; Soares-da-Silva, Patrício // Drugs in R&D;2008, Vol. 9 Issue 6, p447 

    Objective: To investigate the dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate (ESL) in healthy volunteers. Methods: This was a randomized, three-way crossover, single-centre study in 18 healthy volunteers. Subjects received a single dose of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics